Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9PM2E
|
|||
| Drug Name |
IGV-001
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Glioblastoma [ICD-11: 2A00] | Phase 1 | [1] | |
| Company |
Imvax
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04485949) A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.